Union, NJ, United States of America

Fernando Camacho


Average Co-Inventor Count = 8.2

ph-index = 2

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2003-2009

Loading Chart...
3 patents (USPTO):

Title: Innovations of Fernando Camacho

Introduction

Fernando Camacho is an accomplished inventor based in Union, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target central nervous system diseases and disorders. With a total of 3 patents to his name, Camacho's work is recognized for its potential therapeutic applications.

Latest Patents

Camacho's latest patents include innovative compounds such as substituted 1H-pyrrolo[2,3-c]pyridine-2-carboxamides. These compounds are designed as inhibitors of casein kinase Iε, which are effective in treating mood disorders and sleep disorders. The patent also covers pharmaceutical compositions comprising these compounds and methods for their preparation. Another notable patent involves substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides, which serve as inhibitors of human casein kinase IF, further emphasizing their utility in addressing central nervous system conditions.

Career Highlights

Fernando Camacho is currently employed at Aventis Pharmaceuticals Inc., where he continues to innovate and develop new pharmaceutical solutions. His work has been instrumental in advancing the understanding and treatment of various neurological disorders.

Collaborations

Throughout his career, Camacho has collaborated with notable colleagues, including William Arthur Metz, Jr. and Frank Halley. These partnerships have contributed to the successful development of his patented inventions.

Conclusion

Fernando Camacho's contributions to pharmaceutical innovation highlight his commitment to improving treatments for central nervous system disorders. His patents reflect a deep understanding of medicinal chemistry and a dedication to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…